We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.59 | -0.77% | 75.76 | 74.65 | 76.55 | 75.93 | 75.545 | 75.84 | 6,457,295 | 01:00:00 |
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that a combination of its Imfinzi immunotherapy with tremelimumab antibodies showed an unprecedented survival rate in liver-cancer patients.
The London-listed pharmaceutical company said results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi showed unprecedented survival in first-line unresectable liver cancer. It said that 31% of patients were alive at three years.
The company said that the combination--known as the STRIDE regimen--also showed no increase in severe liver toxicity and that no bleeding risk was observed.
Separately, AstraZeneca said Imfinzi plus chemotherapy reduced the risk of death by 20% in first-line advanced biliary tract cancer when compared with chemotherapy on its own.
"Positive results from the Topaz-1 Phase III trial showed AstraZeneca's Imfinzi, in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 19, 2022 02:59 ET (07:59 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions